Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Adenomyosis 1

Interventions

venetoclax 188Azacitidine 160Cytarabine 127fludarabine 96Cyclophosphamide 74Specimen Handling 68fludarabine phosphate 56Daunorubicin 53Biopsy 49Decitabine 47Whole-Body Irradiation 42Mycophenolic Acid 40Idarubicin 40Busulfan 37Tacrolimus 35Injections 35Granulocyte Colony-Stimulating Factor 35Melphalan 32Stem Cell Transplantation 30gilteritinib 25Filgrastim 25CPX-351 25decitabine and cedazuridine drug combination 23Peripheral Blood Stem Cell Transplantation 22Etoposide 20Mitoxantrone 19Cladribine 19ivosidenib 18Thiotepa 17Sirolimus 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Triamcinolone × 1 year × Clear all
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡